Two-Pronged attack on deadly eye cancer
NCT ID NCT02068586
Summary
This study is testing whether taking one of two oral medications—sunitinib or valproic acid—for 6 to 12 months can help prevent a high-risk form of eye melanoma from spreading to other parts of the body after initial treatment. It involves 210 patients who have already had their primary eye tumor removed or treated with radiation. The goal is to see if these drugs can improve survival and keep the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IRIS MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.